Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia

Tselepis, Alexandros D.; Hahalis, George; Tellis, Constantinos C.; Papavasiliou, Eleni C.; Mylona, Panagiota; Kourakli, Alexandra; Alexopoulos, Dimitrios

doi:10.1194/jlr.m007229

Cited by 22 publications

(13 citation statements)

References 45 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is reported that free heme and the red cell membrane elements that are producedduring hemolysis have a negative effect on nitric oxide and arginine availability and therefore thatimpaired nitric oxide bioavailability may represent the central feature of endothelial dysfunction, and pervasively contributes to the overlapping mechanisms of vasculopathies observed in β-TI [6,26]. In addition, high HDL-associated phospholipase A 2 levels, attributed to increased enzyme secretion from monocytes/macrophages and to the predominance of small dense LDL particles in plasma, have been observed in β-TI [27]. …”

Section: Discussionmentioning

confidence: 99%

Evidence for a Proatherogenic Biochemical Phenotype in Beta Thalassemia Minor and Intermedia

Lai

Vacquer²,

Carta³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

The purpose of this study was to focus on pathophysiological mechanisms linking β-thalassemia intermedia (β-TI) and minor (β-TMI) with cardiovascular risk. Iron status, prooxidant-antioxidant balance and lipid profiles in serum, and lipid content in peripheral blood mononuclear cells (PBMCs) were evaluated in 20 β-TMI subjects, 22 β-TI patients and in 30 nonthalassemic blood donors. The mRNA levels of some genes involved in the regulation of iron and cholesterol metabolism were also determined. In β-TI and in β-TMI, serum iron, prooxidant-antioxidant ratio, transferrin saturation and erythropoietin levels were higher, while transferrin and hepcidin were lower compared to controls. Hepcidin and interleukin-1α mRNA levels were found to be reduced in β-TI- and β-TMI-PBMCs, while those of tumor necrosis factor alpha were increased. A reduction in high-density lipoprotein cholesterol in serum and an accumulation of neutral lipids coupled with increased mRNA levels of acetyl-coenzyme A:cholesterol acyltransferase and decreased neutral cholesterol ester hydrolase in PBMCs were also observed in β-TI and β-TMI compared to controls. Taken together, these findings provide experimental support for the idea that not only β-TI patients but also β-TMI have a proatherogenic biochemical phenotype which may contribute to increase their cardiovascular disease risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence for a Proatherogenic Biochemical Phenotype in Beta Thalassemia Minor and Intermedia

Lai

Vacquer²,

Carta³

et al. 2011

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…This association between Lp-PLA 2 mass/activity and first ischemic stroke was confirmed in the Malmo Diet and Cancer Study [66], Bruneck Study [67], and Cardiovascular Health Study [28]. The Tsekepis et al study [68] showed that Lp-PLA 2 correlated with the intima-media thickness in patients with beta-thalassemia, suggesting that Lp-PLA 2 may be implicated in premature carotid atherosclerosis.…”

Section: Association Of Lp-pla 2 With Cardiovascular Disease Riskmentioning

confidence: 81%

Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

Stanković¹,

Ašanin²

2015

Lipoproteins - From Bench to Bedside

View full text Add to dashboard Cite

Within the last decade, a broad range of biomarkers associated with an increased risk for death and cardiovascular/cerebrovascular endpoints have been identified. Epidemiological studies clearly indicate that lipoprotein-associated phospholipase A Lp-PLA has the potential to become clinically useful emerging biomarker in the true sense, linking plaque biology with cardiovascular/cerebrovascular event rate. Lipoprotein-associated phospholipase A is a specific vascular inflammatory marker, a risk factor, a prognostic biomarker, and also a therapeutic target. This chapter will summarize our current knowledge on Lp-PLA with emphasis on its potential pathophysiological mechanisms of action and on clinical relevance as cardiovascular/ cerebrovascular biomarker. This chapter gives comprehensive, systematic review of studies assessing the significance of Lp-PLA in cardiovascular/cerebrovascular diseases with emphasis on clinical benefit of pharmacologic inhibition of Lp-PLA .

show abstract

“…Lp-PLA2 is regarded as a highly specific biomarker for vascular inflammation and burden of atherosclerosis [ 19 ]. The correlation between this biomarker and atherosclerosis is well studied in the general population, as well as in other inflammatory diseases; however there are also contradictory results [ 20 , 21 , 23 – 27 ]. After five years following a diagnosis of RA, the levels of Lp-PLA2 found at inclusion could still explain the extent of atherosclerosis measured by IMT and FMD in patients with RA.…”

Section: Discussionmentioning

confidence: 99%

“…Non-HDL-cholesterol was calculated as total cholesterol minus HDL-cholesterol. Based on previously published data [ 20 ], calculations showed that a sample size of 71 would render 99% power to detect a correlation between IMT and Lp-PLA2 with a correlation coefficient of 0.46. p values < 0.05 were considered statistically significant. All calculations were made using SPSS 20.0 (SPSS Inc., Chicago, USA).…”

Section: Methodsmentioning

confidence: 99%

“…In the general population, higher concentrations of Lp-PLA2 have also been shown to be associated with an increased risk of CVD [ 18 ]. Previous studies of patients with thalassemia, metabolic syndrome, or human immunodeficiency virus (HIV) infection, each diagnosis being characterised by an increased inflammation, have shown an association between Lp-PLA2 and subclinical atherosclerosis measured by IMT [ 20 , 23 , 24 ]. In populations without a known inflammation, however, the results are contradictory [ 21 , 25 – 27 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Södergren

Karp

Bengtsson

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Objective. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a marker of vascular inflammation, is associated with cardiovascular disease. This prospective study of an inception cohort aimed to investigate whether the level of Lp-PLA2 is associated with subclinical atherosclerosis in patients with rheumatoid arthritis (RA). Methods. Patients from northern Sweden diagnosed with early RA were consecutively recruited into an ongoing prospective study. From these, all patients ≤60 years (n = 71) were included for measurements of subclinical atherosclerosis at inclusion (T0) and five years later (T5). Forty age- and sex-matched controls were included. The patients were clinically assessed, SCORE, Reynolds Risk Score, and Larsen score were calculated, and blood samples were drawn from all individuals at T0 and T5. Results. There was no significant difference in the level of Lp-PLA2 between patients with RA and controls (p > 0.05). In simple linear regression models among patients with RA, Lp-PLA2 at T0 was significantly associated with intima media thickness (IMT) at T0 and T5, flow mediated dilation (FMD) at T0 and T5, ever smoking, male sex, HDL-cholesterol (inversely), non-HDL-cholesterol, SCORE, Reynolds Risk Score, and Larsen score (p < 0.05). Conclusion. In this cohort of patients with early RA, the concentration of Lp-PLA2 was associated with both subclinical atherosclerosis and disease severity.

show abstract

Plasma levels of lipoprotein-associated phospholipase A2 are increased in patients with β-thalassemia

Cited by 22 publications

References 45 publications

Evidence for a Proatherogenic Biochemical Phenotype in Beta Thalassemia Minor and Intermedia

Evidence for a Proatherogenic Biochemical Phenotype in Beta Thalassemia Minor and Intermedia

Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Contact Info

Product

Resources

About